Update on Selected Adverse Events of Concern Following Immunization With Acellular Pertussis Vaccines, a Narrative Review - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Review of Notable Adverse Events Associated with Acellular Pertussis Vaccination: A Narrative Overview

  • By

  • Lennart Nilsson

  • Jann Storsaeter

  • July 12, 2026

Share

  • 1

    Acellular pertussis vaccines were developed in the 1970s and 1980s, showing proven efficacy in clinical trials.

  • 2

    Systematic surveillance for adverse events following immunization (AEFI) was initiated when acellular vaccines were introduced.

  • 3

    Mild adverse events from acellular pertussis vaccines include local reactions and systemic symptoms, with lower rates than whole-cell vaccines.

  • 4

    Moderate adverse events include fever, extensive limb swelling, and hypotonic hyporesponsive episodes, particularly in infants.

  • 5

    Hypotonic hyporesponsive episodes typically occur within 48 hours of vaccination, primarily affecting infants under 6 months.

Original Source(s)

Update on Selected Adverse Events of Concern Following Immunization With Acellular Pertussis Vaccines, a Narrative Review

  • by Lennart Nilsson, Jann Storsaeter

  • July 12, 2026

Related Content

FDA expands weekly insulin use to children

Insulin icodec-abae offers a weekly basal insulin option for pediatric type 2 diabetes, supported by adult trials and pediatric pharmacokinetic data.

A Real-World Evidence Study on U.S. Patients Demonstrating Safety of High-Frequency Use of the Remote Electrical Neuromodulation (REN) Wearable Device for Migraine Treatment

This real-world observational study evaluates the safety and tolerability of remote electrical neuromodulation (REN; Nerivio®) in patients who have utilized it more frequently than the current label indication for migraine treatment.

  • by

  • October 19, 2026

  • 2 min
FDA adds generic valganciclovir oral solution

 The new option is indicated for CMV prophylaxis in pediatric kidney and heart transplant recipients, as well as adult CMV retinitis and transplant prophylaxis.